Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657866 | 0.71 | RAB9A (0.54) | ALDH1A1MAPTSMN1; SMN2ALOX15LMNA | |
| SCHEMBL1252549 | 0.71 | PARP1 (0.61) | ALDH1A1PARP1 | |
| SCHEMBL17927741 | 0.70 | HCAR2 (0.39) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL7399854 | 0.69 | HTR1A (0.73) | — | |
| SCHEMBL31672497 | 0.68 | L3MBTL1 (0.56) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL14430755 | 0.68 | ACHE (0.45) | KMT2AMAPTL3MBTL1RECQLTSHR | |
| Hydrochloric Acid SCHEMBL1251976 | 0.68 | PARP1 (0.60) | ALDH1A1GAASMN1; SMN2PARP1 | |
| SCHEMBL2219175 | 0.68 | KMT2A (1.00) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL3896010 | 0.67 | EPHX1 (0.54) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL5488104 | 0.67 | KDM4E (0.57) | ALDH1A1GAASMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | KMT2A 234/4885MEN1 4813/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.